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Renal replacement therapy (RRT) is necessary for the survival
of patients with end-stage renal disease (ESRD) both prior to
kidney transplantation or in patients where kidney transplan-
tation is not available. Peritoneal dialysis (PD) and hemodial-
ysis (HD) are lifesaving RRTs formore than 2million patients
with ESRD worldwide [1]. As the incidence of chronic
renal disease has doubled over the past decade, the number
of patients with ESRD is expected to increase by 5–8%
annually [2]. Although long-term morbidity and mortality
are comparable between PD and HD, there is an early patient
survival advantage for PD and a better quality of life [3].
Moreover PD is cost-effective as compared to hospital-based
HD [4]. Nevertheless only one out of 10 patients is treated
with PD, which suggests a general underutilization [5]. PD is
a simple therapy in which PD fluid is exchanged several times
a day; themajor limitations are peritonealmembrane damage
on the long-term and infection [6]. PD could be largely
enhanced if one can identify diagnostic and therapeutic
tools to improve PD outcome that promote function of the
peritoneal membrane and prevent infectious complications
[7]. European Training and Research in Peritoneal Dialysis
(EuTRiPD) is an EU funded training programme, in which
exactly these goals are targeted [8].
In this special issue of BMRI, we present a number of
articles prepared in part (but also by other contributors)
with a support from the EuTRiPD initiative. These are both
original research papers and review papers that (i) analyze
basic aspects of peritoneal cell biology using in vitromethods,
(ii) mimic clinical situations in relevant PD models in
rodents, and (iii) describe the outcomes of clinical studies
using new biomarkers or new interventions.
In the following papers, firstly studies apply in vitro
models to investigate the senescence-associated proteome
in mesothelial cells, the effect of differently sterilized PD
fluids onmesothelial stress responses, and the contribution of
mesothelial-to-mesenchymal transition to peritoneal fibrob-
last expansion. Secondly with respect to papers in rodent PD
models a new mouse uremic model is presented, the effect of
rapamycin in a mouse model is shown, and moreover clear
indications are described in protective effect of paricalcitol
in a PD model and another PD-fibrosis-like model. Thirdly
clinical material was used in studies showing the importance
of, respectively, HA, microRNA, osmolarity of fluid, and
tenascin-C levels reflecting peritoneal patient status. Finally
underutilization of PD is discussed as originating from less
education and referral pattern and moreover it is discussed
that new biomarkers in PD could contribute significantly to
making choices for the future as shown by EuTRiPD. The
editors feel that all these papers give a good overview of the
state of art in addressing all aspects of PD.
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